ClinicalTrials.gg
CompletedNCT04569136Updated Jul 18, 2024Results posted

Physical Therapy Intervention for Puerperal Mastitis

An interventional study of Education and Therapeutic ultrasound in Mastitis, sponsored by National Cheng Kung University. Completed at 1 site in Taiwan. Open to female participants aged 21 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-07-18.

Sponsored by National Cheng Kung University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
21 Years to 35 Years
Sex
Female
01

Study summary

Puerperal mastitis is one of the most commonly reported problems during breastfeeding. Women frequently report breast pain, tenderness, redness, engorgement, fever, malaise, chills, lethargy, sweating, headache, nipple damage and a hot spot on the affected breast. These highly distressing symptoms may severely impact on a woman's daily activities and quality of life and might lead to the premature cessation of exclusive breastfeeding, which may have significant impact on infant health and survival. The role of physical therapy in reducing pregnancy/postpartum-related disorders including breast problems is gaining momentum and importance in obstetrics. However, to date, only low-level evidence has shown positive effects of breast massage, a physical technique, on pain, milk supply and symptom relief in women with breastfeeding problems. This is encouraging, however further research is needed to explore whether physical therapy is effective to reduce symptoms of puerperal mastitis. The investigators will conduct a prospective, assessor blinded single-center randomized controlled trial to assess the effectiveness of an individualized physical therapy program with therapeutic ultrasound, education and massage for patients with puerperal mastitis, compared to patients receiving usual obstetric care and sham ultrasound treatment.

Read the detailed description

The high incidence of mastitis in breastfeeding women places health professionals working with postpartum women in key positions for managing women for symptoms of mastitis. This study aims to investigate the effectiveness of a physical therapy program for mastitis. The data the investigators collect from this study will provide evidence on effective and targeted strategies to achieve the goals of acceptable, effective and low risk physical therapy treatment of mastitis in postpartum women. Once these perspectives are known, recommendations on mastitis management can be made.

02

Conditions studied

  • Mastitis

Browse trials for

03

In context

Mastitis

31 studies on the registry are indexed under Mastitis; 7 are open to participants now.

This study's enrollment of 37 is below the median of 114 across 16 interventional studies indexed under Mastitis.

Browse Mastitis studies →

Lead sponsor

National Cheng Kung University is the lead sponsor of 63 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have given birth at National Cheng Kung University Hospital (NCKUH)
  • Are Breastfeeding
  • Are aged 21-35
  • Are diagnosed with early stage mastitis
  • Have sufficient Chinese/Mandarin language skills to participate

Exclusion criteria

Exclusion Criteria:

  • History of breast reduction or augmentation
  • An abscess
  • Severe physical/psychiatric impairments
  • Presence of any
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Intervention group

    * Educating the patient about mastitis and self-management strategies * Treating with therapeutic ultrasound * Administering and teaching breast massage

    Other: Education · Other: Therapeutic ultrasound · Other: Breast massage

  • Sham comparator
    Sham group

    * Educating the patient about mastitis and self-management strategies * Receiving sham ultrasound * Administering and teaching breast massage

    Other: Education · Other: Sham ultrasound · Other: Breast massage

  • Other
    Usual care group

    Receiving usual obstetric care, which may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff

    Other: Usual obstetric care

Interventions

  • OtherEducation

    The education session including education about mastitis, feeding techniques, lifestyle changes, thermal/cryo therapy and demonstration of breast self-massage will take approximately 20 minutes.

  • OtherTherapeutic ultrasound

    Participants will be treated with 5 minutes of therapeutic ultrasound (pulsed mode) at a frequency of 1 Mega Hertz, a duty cycle of 20%, a pulse intensity of 1.8 Watt/centimetre squared. The ultrasound probe will be moved at a speed of about 4 centimetre/second. The intensity and duration will be adjusted if the patient complains of discomfort. The ultrasound transducer head will massage over the tender point on the breast.

  • OtherSham ultrasound

    Participants will receive 5 minutes of 'sham' ultrasound at 0 Watt/centimetre squared intensity from a physical therapist.

  • OtherBreast massage

    Breast massage includes general and focused massage. Participants will lie in supine position. The breast massage will be applied according to the Vodder method to the affected breast.

  • OtherUsual obstetric care

    Usual obstetric care may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff.

06

What researchers measure

Primary outcomes

  1. Breast and Nipple Pain

    Breast and nipple pain in the past 24 hours will be assessed using the numerical rating scale (NRS). Participants will be asked to rate her breast pain and nipple pain from 0 to 10 (11 point scale), with 0 indicating no pain and 10 indicating the worst possible pain.

    Time frame: 3 months

Secondary outcomes

  1. Severity of Breast Engorgement

    The degree of breast engorgement of the left and right breasts will be assessed using a six-point engorgement scale developed by Hill and Humenick. The higher scores indicate more severe breast engorgement (1=soft, no change, 2=slight change, 3=firm, non-tender, 4=firm, beginning tenderness, 5=firm, tender, 6=very firm and very tender).

    Time frame: 3 months

  2. Breast Hardness

    The assessor will use a portable durometer to measure the hardness of left and right breasts. The participant will lie in a supine position and the durometer will be placed at 3 cm from both nipples in the 10 o'clock and 2 o'clock positions. The spring-loaded presser is pressed downwards until trigger switch on. Each position will be measured three times and the mean value will be obtained. The values range from 0-100. Higher values represent a worse outcome.

    Time frame: 3 months

  3. Body and Breast Temperature

    Core body and breast temperatures will be measured using a non-contact infrared thermometer on the central part of the forehead and in the area 3 cm from both nipples in the 10 o'clock and 2 o'clock positions, respectively. The temperature of each position will be measured three times and the mean value will be recorded.

    Time frame: 3 months

  4. Volume of Mother's Milk

    The volume of mother's milk will be measured by an electric breast pump for 15 minutes. Milk volumes will be recorded by weighing the collecting bottle on an electronic digital scale to the nearest 0.1 gram before and after each expression.

    Time frame: 3 months

  5. Acceptability of the Intervention Program

    Acceptability of the intervention program will be assessed immediately post-intervention using a short questionnaire with 5-point Likert scale response to questions of 'how acceptable did you find the physical therapy interventions used in this study?' and 'how would you rate your overall satisfaction with the physical therapy program?' from 1 to 5, with 1 indicating very low acceptability or satisfaction and 5 indicating very high acceptability or satisfaction. The number of participants who rate a 5 (i.e. very high) on acceptability and satisfaction will be counted and recorded.

    Time frame: 3 months

  6. Number of Participants Reporting Adverse Events

    Adverse events will be recorded and reported as per Institutional Review Board, National Cheng Kung University Hospital guidelines on reporting adverse events and serious adverse events, with the absence of adverse or serious adverse events related to the physical therapy intervention used to indicate safety of the trial protocol.

    Time frame: 3 months

  7. Breastfeeding Self-efficacy

    Breastfeeding self-efficacy will be evaluated using the Breastfeeding Self-Efficacy Scale - Short Form (BSES-SF). The BSES-SF is a validated and reliable patient-reported outcome measure consisting of 14 items. Each item is scored between 1-5 points with 1 indicating 'not at all confident' and 5 indicating 'always confident'. Total scores range from 14 to 70, with higher scores indicating higher breastfeeding self-efficacy.

    Time frame: 3 months

07

Results

Posted Jul 18, 2024

Participant flow

Participant flow — Overall Study
MilestoneIntervention GroupSham GroupUsual Care Group
Started121213
Completed101212
Not completed201
Withdrew: Lost to follow-up201

Outcome measures

PrimaryBreast and Nipple Pain

Breast and nipple pain in the past 24 hours will be assessed using the numerical rating scale (NRS). Participants will be asked to rate her breast pain and nipple pain from 0 to 10 (11 point scale), with 0 indicating no pain and 10 indicating the worst possible pain.

Time frame:
3 months
Reported as:
Median · score on a scale
Breast and Nipple Pain
score on a scaleIntervention GroupSham GroupUsual Care Group
Breast and Nipple Pain0 (0 to 0.75)0 (0 to 0)1 (0 to 2)
SecondarySeverity of Breast Engorgement

The degree of breast engorgement of the left and right breasts will be assessed using a six-point engorgement scale developed by Hill and Humenick. The higher scores indicate more severe breast engorgement (1=soft, no change, 2=slight change, 3=firm, non-tender, 4=firm, beginning tenderness, 5=firm, tender, 6=very firm and very tender).

Time frame:
3 months
Reported as:
Median · score on a scale
Severity of Breast Engorgement
score on a scaleIntervention GroupSham GroupUsual Care Group
Severity of Breast Engorgement1 (1 to 2)1.5 (1 to 2)2 (1 to 3)
SecondaryBreast Hardness

The assessor will use a portable durometer to measure the hardness of left and right breasts. The participant will lie in a supine position and the durometer will be placed at 3 cm from both nipples in the 10 o'clock and 2 o'clock positions. The spring-loaded presser is pressed downwards until trigger switch on. Each position will be measured three times and the mean value will be obtained. The values range from 0-100. Higher values represent a worse outcome.

Time frame:
3 months
Reported as:
Median · units on a scale
Breast Hardness
units on a scaleIntervention GroupSham GroupUsual Care Group
Breast Hardness5.2 (2.8 to 7.4)1.0 (0.2 to 5.9)2.3 (1.1 to 3.7)
SecondaryBody and Breast Temperature

Core body and breast temperatures will be measured using a non-contact infrared thermometer on the central part of the forehead and in the area 3 cm from both nipples in the 10 o'clock and 2 o'clock positions, respectively. The temperature of each position will be measured three times and the mean value will be recorded.

Time frame:
3 months
Reported as:
Median · Degrees Celsius
Body and Breast Temperature
Degrees CelsiusIntervention GroupSham GroupUsual Care Group
Body and Breast Temperature36.9 (36.7 to 37.3)36.7 (36.6 to 37.1)37.0 (36.7 to 37.4)
SecondaryVolume of Mother's Milk

The volume of mother's milk will be measured by an electric breast pump for 15 minutes. Milk volumes will be recorded by weighing the collecting bottle on an electronic digital scale to the nearest 0.1 gram before and after each expression.

Time frame:
3 months
Reported as:
Median · g
Volume of Mother's Milk
gIntervention GroupSham GroupUsual Care Group
Volume of Mother's Milk52.2 (20.6 to 81.5)17.8 (2.6 to 35.3)40.7 (16.9 to 112.0)
SecondaryAcceptability of the Intervention Program

Acceptability of the intervention program will be assessed immediately post-intervention using a short questionnaire with 5-point Likert scale response to questions of 'how acceptable did you find the physical therapy interventions used in this study?' and 'how would you rate your overall satisfaction with the physical therapy program?' from 1 to 5, with 1 indicating very low acceptability or satisfaction and 5 indicating very high acceptability or satisfaction. The number of participants who rate a 5 (i.e. very high) on acceptability and satisfaction will be counted and recorded.

Time frame:
3 months
Reported as:
Count of participants · Participants
Acceptability of the Intervention Program
ParticipantsIntervention GroupSham GroupUsual Care Group
Acceptability of the Intervention Program11117
SecondaryNumber of Participants Reporting Adverse Events

Adverse events will be recorded and reported as per Institutional Review Board, National Cheng Kung University Hospital guidelines on reporting adverse events and serious adverse events, with the absence of adverse or serious adverse events related to the physical therapy intervention used to indicate safety of the trial protocol.

Time frame:
3 months
Reported as:
Count of participants · Participants
Number of Participants Reporting Adverse Events
ParticipantsIntervention GroupSham GroupUsual Care Group
Number of Participants Reporting Adverse Events000
SecondaryBreastfeeding Self-efficacy

Breastfeeding self-efficacy will be evaluated using the Breastfeeding Self-Efficacy Scale - Short Form (BSES-SF). The BSES-SF is a validated and reliable patient-reported outcome measure consisting of 14 items. Each item is scored between 1-5 points with 1 indicating 'not at all confident' and 5 indicating 'always confident'. Total scores range from 14 to 70, with higher scores indicating higher breastfeeding self-efficacy.

Time frame:
3 months
Reported as:
Median · score on a scale
Breastfeeding Self-efficacy
score on a scaleIntervention GroupSham GroupUsual Care Group
Breastfeeding Self-efficacy52.0 (40.0 to 58.0)59.5 (34.25 to 68.75)55 (52.5 to 59.5)

Adverse events

Collected over 2 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intervention Group0/12 (0%)0/12 (0%)0/12 (0%)
Sham Group0/12 (0%)0/12 (0%)0/12 (0%)
Usual Care Group0/13 (0%)0/13 (0%)0/13 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Intervention GroupSham GroupUsual Care GroupTotal
Mean34.5 ± 3.333.6 ± 3.734.2 ± 4.434.1 ± 3.7
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Intervention GroupSham GroupUsual Care GroupTotal
Female12121337
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Intervention GroupSham GroupUsual Care GroupTotal
Count of participants———0
Body mass index
Body mass index(kg/m^2)Intervention GroupSham GroupUsual Care GroupTotal
Mean24.6 ± 3.424.1 ± 3.724.0 ± 3.724.2 ± 3.5
Waist-hip ratio
Waist-hip ratio(Ratio)Intervention GroupSham GroupUsual Care GroupTotal
Mean0.83 ± 0.040.82 ± 0.060.82 ± 0.040.83 ± 0.04
08

Study locations

1 site
  • National Cheng Kung University
    Tainan, 704, Taiwan
09

References and documents

Publications

  • Diepeveen LC, Fraser E, Croft AJE, Jacques A, McArdle AM, Briffa K, McKenna L. Regional and Facility Differences in Interventions for Mastitis by Australian Physiotherapists. J Hum Lact. 2019 Nov;35(4):695-705. doi: 10.1177/0890334418812041. Epub 2018 Nov 27. PubMed 30481473 ↗
  • Kasseroller RG. The Vodder School: the Vodder method. Cancer. 1998 Dec 15;83(12 Suppl American):2840-2. doi: 10.1002/(sici)1097-0142(19981215)83:12b+3.0.co;2-5. PubMed 9874409 ↗
  • Lavigne V, Gleberzon BJ. Ultrasound as a treatment of mammary blocked duct among 25 postpartum lactating women: a retrospective case series. J Chiropr Med. 2012 Sep;11(3):170-8. doi: 10.1016/j.jcm.2012.05.011. PubMed 23449233 ↗
  • McLachlan Z, Milne EJ, Lumley J, Walker BL. Ultrasound treatment for breast engorgement: A randomised double blind trial. Aust J Physiother. 1991;37(1):23-8. doi: 10.1016/S0004-9514(14)60531-6. PubMed 25026196 ↗
  • Witt AM, Bolman M, Kredit S, Vanic A. Therapeutic Breast Massage in Lactation for the Management of Engorgement, Plugged Ducts, and Mastitis. J Hum Lact. 2016 Feb;32(1):123-31. doi: 10.1177/0890334415619439. Epub 2015 Dec 7. PubMed 26644422 ↗
  • Wong RA, Schumann B, Townsend R, Phelps CA. A survey of therapeutic ultrasound use by physical therapists who are orthopaedic certified specialists. Phys Ther. 2007 Aug;87(8):986-94. doi: 10.2522/ptj.20050392. Epub 2007 Jun 6. Erratum In: Phys Ther. 2007 Sep;87(9):1258. PubMed 17553923 ↗
  • Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52. doi: 10.1002/acr.20543. No abstract available. PubMed 22588748 ↗
  • Hill PD, Humenick SS. The occurrence of breast engorgement. J Hum Lact. 1994 Jun;10(2):79-86. doi: 10.1177/089033449401000212. PubMed 7619260 ↗
  • Lim AR, Song JA, Hur MH, Lee MK, Lee MS. Cabbage compression early breast care on breast engorgement in primiparous women after cesarean birth: a controlled clinical trial. Int J Clin Exp Med. 2015 Nov 15;8(11):21335-42. eCollection 2015. PubMed 26885074 ↗
  • Geissler NJ. An instrument used to measure breast engorgement. Nurs Res. 1967 Spring;16(2):130-6. No abstract available. PubMed 5181912 ↗
  • Mori H, Uemura N, Koga H, Okazaki M. Objective assessment of reconstructed breast hardness using a durometer. Breast Cancer. 2018 Jan;25(1):81-85. doi: 10.1007/s12282-017-0791-y. Epub 2017 Jun 23. PubMed 28646371 ↗
  • Teran CG, Torrez-Llanos J, Teran-Miranda TE, Balderrama C, Shah NS, Villarroel P. Clinical accuracy of a non-contact infrared skin thermometer in paediatric practice. Child Care Health Dev. 2012 Jul;38(4):471-6. doi: 10.1111/j.1365-2214.2011.01264.x. Epub 2011 Jun 8. PubMed 21651612 ↗
  • Jones E, Dimmock PW, Spencer SA. A randomised controlled trial to compare methods of milk expression after preterm delivery. Arch Dis Child Fetal Neonatal Ed. 2001 Sep;85(2):F91-5. doi: 10.1136/fn.85.2.f91. PubMed 11517200 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Apr 2023, 28 months.

Results were first posted in Jul 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2020
First posted
Sep 29, 2020
StartActual
Dec 1, 2020
Primary completionActual
Apr 27, 2023
CompletionActual
Apr 27, 2023
Results first posted
Jul 18, 2024
Last update
Jul 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04569136
Lead sponsor
National Cheng Kung University
Collaborators
Ministry of Science and Technology, Taiwan
Responsible party
Kuan-Yin Lin (Assistant professor, National Cheng Kung University) — Principal investigator
First posted
Sep 29, 2020
Start date
Dec 1, 2020
Primary completion
Apr 27, 2023
Completion
Apr 27, 2023
Results posted
Jul 18, 2024
Last update
Jul 18, 2024

Study contacts

Kuan-Yin Lin, PhD
principal investigator · National Cheng Kung University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion